The clinical effectiveness and costeffectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: Systematic reviews, registry database analyses and economic evaluation

Health Technology Assessment

Volumn 15, Issue 34, 2011, Pages

  Robertson, C ^a   Arcot Ragupathy, S K ^b   Boachie, C ^a   Dixon, J M ^c   Fraser, C ^a   Hernandez R ^a,d   Heys, S ^b   Jack, W ^c   Kerr, Gr ^c   Lawrence, G ^e   MacLennan, G ^a   Maxwell, A ^f   McGregor, J ^g   Mowatt, G ^a   Pinder, S ^h   Ternent, L ^a,c   Thomas, R E ^a   Vale, L ^a,c   Wilson, R ⁱ   Zhu, S ^a   Gilbert, F J ^d   more..

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f ROYAL BOLTON HOSPITAL   (United Kingdom)

^g Breast Cancer Care   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; BREAST CONSERVATIVE SURGERY; BREAST SELF EXAMINATION; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EXAMINATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOMAMMOGRAPHY; HUMAN; IPSILATERAL BREAST TUMOR RECURRENCE; MAMMOGRAPHY; MASTECTOMY; METACHRONOUS CONTRALATERAL BREAST CANCER; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SURVEILLANCE MAMMOGRAPHY; SYSTEMATIC REVIEW;

EID: 82455198707     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta15340     Document Type: Review

References (125)

1. Cancer Research UK. Prostate cancer: survival statistics. London: Cancer Research UK; 2009. URL: http://info.cancerresearchuk.org/cancerstats/types/prostate/survival/index.htm (accessed April 2010).
2. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
4. Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer 2007;97:1631-41.
5. Lu WL. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 2009;114:403-12.
6. Schootman M, Fuortes L, Aft R. Prognosis of metachronous contralateral breast cancer according to stage at diagnosis: the importance of early detection. Breast Cancer Res Treat 2006;99:91-5.
7. della Rovere GQ, Benson JR. Ipsilateral local recurrence of breast cancer: determinant or indicator of poor prognosis? Lancet Oncol 2002;3:183-7.
8. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-97.
9. Houghton J, ATAC Trialists' Group. A detailed analysis of the risk factors influencing local and distant breast cancer recurrence during adjuvant endocrine therapy. J Clin Oncol 2007;25:S562.
10. Benson JR, della Rovere GQ. Ipsilateral breast cancer recurrence. Breast 2008;17:12-18.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
12. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4.
13. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 2009;45:1649-53.
14. Cancer Research UK. Breast cancer: UK incidence statistics. London: Cancer Research UK; 2009. URL: http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/index.htm (accessed January 2010).
15. Cajucom CC, Tsangaris TN, Nemoto T, Driscoll D, Penetrante RB, Holyoke ED. Results of salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy. Cancer 1993;71:1774-9.
16. Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 1984;71:711-14.
17. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:855-61.
18. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, et al. Cancer prevalence in the United Kingdom: estimates for 2008. Br J Cancer 2009;101:541-7.
19. Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993;11:44-8.
20. Haffty BG, Fischer D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 1991;21:293-8.
21. Association of Breast Surgeons at the British Association of Surgical Oncology (ABS at BASO). Surgical guidelines for the management of breast cancer. Eur J Surg Oncol 2009;35(Suppl. 1):1-22.
22. Scottish Intercollegiate Guidelines Network (SIGN). Management of breast cancer in women. SIGN Clinical Guideline no. 84. Edinburgh: SIGN; 2005. URL: www.sign.ac.uk/pdf/sign84.pdf (accessed January 2010).
23. Board of the Faculty of Clinical Radiology. Guidance on screening and symptomatic breast imaging. London: The Royal College of Radiologists; 2003. URL: www.rcr.ac.ukindex.asp?PageID=310&PublicationID=184 (accessed January 2010).
24. National Institute for Health and Clinical Excellence (NICE). Early and locally advanced breast cancer: full guideline. NICE CG80. London: NICE; 2009. URL: http://guidance.nice.org.uk/CG80/Guidance/pdf/English (accessed January 2010).
25. National Institute for Health and Clinical Excellence (NICE). Guidance on cancer services. Improving outcomes in breast cancer. London: NICE; 2002. URL: www.nice.org.uk/pdf/Improving_outcomes_breastcancer_manual.pdf (accessed January 2010).
26. Donnelly P, Hiller L, Bathers S, Bowden S, Coleman R. Questioning specialists' attitudes to breast cancer follow-up in primary care. Ann Oncol 2007;18:1467-76.
27. Maxwell AJ, Evans AJ, Carpenter R, Dobson HM, Kearins O, Clements K, et al. Follow-up for screen-detected ductal carcinoma in situ: results of a survey of UK centres participating in the Sloane project. Eur J Surg Oncol 2009;35:1055-9.
28. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006;24:5091-7.
29. Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2000;4:CD001768. DOI: 10.1002/14651858.CD001768.pub2.
30. Flobbe K, van der Linden ES, Kessels AG, van Engelshoven JM. Diagnostic value of radiological breast imaging in a non-screening population. Int J Cancer 2001;92:616-18.
31. Orel SG, Troupin RH, Patterson EA, Fowble BL. Breast cancer recurrence after lumpectomy and irradiation: role of mammography in detection. Radiology 1992;183:201-6.
32. Fowble B, Solin LJ, Schultz DJ, Rubenstein J, Goodman RL. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys 1990;19:833-42.
33. Joseph E, Hyacinthe M, Lyman GH, Busch C, Demps L, Reintgen DS, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol 1998;5:522-8.
34. Bartella L, Smith CS, Dershaw DD, Liberman L. Imaging breast cancer. Radiol Clin North Am 2007;45:45-67.
35. Pisano ED, Hendrick RE, Yaffe MJ, Baum JK, Acharyya S, Cormack JB, et al. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 2008;246:376-83.
36. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008;299:2151-63.
37. Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. AJR Am J Roentgenol 2003;181:177-82.
38. Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology 2001;221:641-9.
39. Buchberger W, DeKoekkoek-Doll P, Springer P, Obrist P, Dunser M. Incidental findings on sonography of the breast: clinical significance and diagnostic workup. AJR Am J Roentgenol 1999;173:921-7.
40. Department of Health. NHS reference costs 2008-09. London: Department of Health; 2010. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 (accessed January 2010).
41. Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ 1996;313:665-9.
42. Breast Cancer.org. Breast self-examination. Ardmore, PA: Breastcancer.org; 2008. URL: www.breastcancer.org/symptoms/testing/types/self_exam/ (accessed January 2010).
43. Barnsley GP, Grunfeld E, Coyle D, Paszat L. Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg 2007;120:1125-32.
44. Collins RF, Bekker HL, Dodwell DJ. Follow-up care of patients treated for breast cancer: a structural review. Cancer Treat Rev 2004;30:19-35.
45. de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol 2004;22:4010-18.
46. Montgomery DA, Krupa K, Cooke TG. Alternative methods of follow up in breast cancer: a systematic review of the literature. Br J Cancer 2007;96:1632-41.
47. Grunfeld E, Noorani H, McGahan L, Paszat L, Coyle D, Van Walraven C, et al. Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast 2002;11:228-35.
48. Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 2009;20:1505-10.
49. Voogd AC. Local recurrence after breast conservation therapy for early stage breast carcinoma detection, treatment, and outcome in 266 patients. Cancer 1999;85:437-46.
50. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36).
51. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. The Cochrane Collaboration, 2009. URL: www.cochrane-handbook.org (accessed January 2010).
52. Centre for Reviews and Dissemination. NHS Economic Evaluation Database handbook. University of York: CRD; 2007. URL: www.york.ac.uk/inst/crd/pdf/nhseed-handb07.pdf (accessed January 2010).
53. Churn M, Kelly V. Outpatient follow-up after treatment for early breast cancer: updated results after 5 years. Clin Oncol 2001;13:187-94.
54. Montgomery DA, Krupa K, Jack WJ, Kerr GR, Kunkler IH, Thomas J, et al. Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 2007;96:1802-7.
55. Montgomery DA, Krupa K, Cooke TG. Locoregional relapse after breast cancer: most relapses occur late and are not clinically detected. Breast J 2009;15:163-7.
56. Paszat L, Sutradhar R, Grunfeld E, Gainford C, Benk V, Bondy S, et al. Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series. Breast Cancer Res Treat 2008;114:169-78.
57. Yau TK, Sze H, Soong IS, Wong W, Chan K, Chang A, et al. Surveillance mammography after breast conservation therapy in Hong Kong: effectiveness and feasibility of risk-adapted approach. Breast 2008;17:132-7.
58. Lash TL, Fox MP, Buist DS, Wei F, Field TS, Frost FJ, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol 2007;25:3001-6.
59. Lash TL, Clough-Gorr K, Silliman RA. Reduced rates of cancer-related worries and mortality associated with guideline surveillance after breast cancer therapy. Breast Cancer Res Treat 2005;89:61-7.
60. Lash TL, Fox MP, Silliman RA. Reduced mortality rate associated with annual mammograms after breast cancer therapy. Breast J 2006;12:2-6.
61. Bossuyt PM, Leeflang MM. Developing criteria for included studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 0.4 (updated September 2008). The Cochrane Collaboration, 2008. URL: http://srdta.cochrane.org/en/authors.html (accessed January 2010).
62. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
63. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:1235-41.
64. Bone B, Aspelin P, Isberg B, Perbeck L, Veress B. imaging of the breast in patients with breast implants after cancer surgery. Acta Radiol 1995;36:111-16.
65. Kim MJ, Kim EK, Kwak JY, Park BW, Kim SI, Sohn J, et al. Sonographic surveillance for the detection of contralateral metachronous breast cancer in an Asian population. AJR Am J Roentgenol 2009;192:221-8.
66. Belli P, Pastore G, Romani M, Terribile D, Canade A, Costantini M. Role of magnetic resonance imaging in the diagnosis of recurrence after breast conserving therapy. Rays 2002;27:241-57.
67. Drew PJ, Kerin MJ, Turnbull LW, Imrie M, Carleton PJ, Fox JN, et al. Routine screening for local recurrence following breast-conserving therapy for cancer with dynamic contrastenhanced magnetic resonance imaging of the breast. Ann Surg Oncol 1998;5:265-70.
68. Mumtaz H, Davidson T, Hall-Craggs MA, Payley M, Walmsley K, Cowley G, et al. Comparison of magnetic resonance imaging and conventional triple assessment in locally recurrent breast cancer. Br J Surg 1997;84:1147-51.
69. Rieber A, Merkle E, Zeitler H, Gorich J, Kreienberg R, Brambs HJ, et al. Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr 1997;21:780-4.
70. Viehweg P, Rotter K, Laniado M, Lampe D, Buchmann J, Kolbl H, et al. MR imaging of the contralateral breast in patients after breast-conserving therapy. Eur Radiol 2004;14:402-8.
71. Shin JH, Han BK, Choe YH, Nam SJ, Park W, Im YH. Ultrasonographic detection of occult cancer in patients after surgical therapy for breast cancer. J Ultrasound Med 2005;24:643-9.
72. Ternier F, Houvenaeghel G, Lecrivain F, Brigand BL, Margain D, Brunelle S, et al. Computed tomography in suspected local breast cancer recurrence. Breast Cancer Res Treat 2006;100:247-54.
73. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, et al. A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-6.
74. Collett D. Modelling survival data in medical research. London: Chapman & Hall/CRC; 2003.
75. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34:187-220.
76. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
77. Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breastconserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 2009;27:2466-73.
78. Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 1991; 338:327-31.
79. Fortin A, Larochelle M, Laverdiere J, Lavertu S, Tremblay D. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 1999;17:101-9.
80. Veronesi U, Marubini E, Del Vecchio M, Manzari A, Andreola S, Greco M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995;87:19-27.
81. Ciatto S, Houssami N, Martinelli F, Bonardi R, Cafferty FH, Duffy SW. Second breast cancers in a Tuscan case series: characteristics, prognosis, and predictors of survival. Br J Cancer 2008;99:539-44.
82. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press; 2005.
83. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) website. University of Oxford: Clinical Trial Service Unit and Epidemiological Studies Unit; 2008. URL: www.ctsu.ox.ac.uk/projects/ebctcg (accessed January 2010).
84. Adjuvant! Online website. Adjuvant! Inc., 2008. URL: www.adjuvantonline.com/index.jsp (accessed January 2010).
85. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-96.
86. NHS Scotland Information and Statistics Division. Breast cancer: data analyses and reports. Edinburgh: NHS Scotland; 2010. URL: www.isdscotland.org/isd/1420.html (accessed January 2010).
87. Government Actuary's Department (GAD). Interim life tables 2006-08. London: GAD; 2008. URL: www.gad/gov.uk/Demography%20Data/Life%20Tables/index.html (accessed January 2010).
88. Spratt JA, von Fournier D, Spratt JS, Weber EE. Mammographic assessment of human breast cancer growth and duration. Cancer 1993;71:2020-6.
89. Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth rate of primary breast cancer. Cancer 1993;71:3547-51.
90. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148:671-9.
91. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
92. Burr J, Mowatt G, Siddiqui MAR, Herandez R, Cook JA, Lourenco T, et al. The clinical and cost effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007;11(41).
93. NHS Breast Screening Programme (NHSBSP) website. NHSBSP, 2009. URL: www.cancerscreening.nhs.uk/breastscreen/index.html#cost (accessed January 2010).
94. Scottish National Breast Screening Programme spreadsheet. Edinburgh: Information Services Division Scotland; 2009. URL: www.isdscotland.org/isd/servlet/FileBuffer?namedFile=Costs_R921_2009.xls&pContentDispositionType=inline (accessed January 2010).
95. Personal Social Services Research Unit (PSSRU). Curtis L. Unit costs of health and social care 2008. Canterbury: PSSRU; 2008. URL: www.pssru.ac.uk.uc/uc/uc2008contents.htm#contents (accessed January 2010).
96. Griffin S, Dunn GPS, Macfarlane K, Brent S, Dyker A, Erhorn S. The use of paclitaxel in the management of early stage breast cancer. The Evidence Review Group's report. London: NICE; 2006. URL: www.nice.org.uk/nicemedia/pdf/STA_report.pdf (accessed January 2010).
97. Prescott RJ, Kunkler IH, Williams LJ, King CC, Jack W, van der Pol M, et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technol Assess 2007;11(31).
98. National Institute for Health and Clinical Excellence (NICE). Breast cancer (early): hormonal treatments: costing template and report. London: NICE; 2006. URL: http://guidance.nice.org.uk/TA112/CostReport/xls/English (accessed January 2010).
99. National Institute for Health and Clinical Excellence (NICE). Docetaxel for the adjuvant treatment of early node-positive breast cancer. TA109. London: NICE; 2006. URL: http://guidance.nice.org.uk/TA109/Guidance/pdf/English (accessed January 2010).
100. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed January 2010).
101. Brennan V, Wolowacz S. A systematic review of breast cancer utility weights. ISPOR 13th Annual International Meeting, Toronto, 3-7 May 2008.
102. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90.
103. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. Br J Cancer 2007;97:152-61.
104. Schleinitz MD, DePalo D, Blume J, Stein M. Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med 2006;21:1253-60.
105. Sorensen S, Brown R, Benedict A, Flood E, Revicki D. Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health 2004;7:641-2.
106. Jansen SJ, Stiggelbout AM, Wakker PP, Vliet Vlieland TP, Leer JW, Nooy MA, et al. Patients' utilities for cancer treatments: a study of the chained procedure for the standard gamble and time trade-off. Med Decis Making 1998;18:391-9.
107. Tosteson AN, Stout NK, Fryback DG, Acharyya S, Herman BA, Hannah LG, et al. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 2008;148:1-10.
108. Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 2007;25:4210-16.
109. Cook JV, Dickinson HO, Eccles MP. Response rates in postal surveys of healthcare professionals between 1996 and 2005: an observational study. BMC Health Serv Res 2009;9:160.
110. Kontos M, Allen D, Trafalis DT, Jones G, Garmo H, Holmberg L, et al. Follow-up may not be beneficial after treatment of grade 1 breast cancer. Br J Surg 2009;96:999-1004.
111. National Breast and Ovarian Cancer Centre (NBOCC). Clinical practice guideline for the management of early breast cancer. Canberra, Australia: National Breast and Ovarian Cancer Centre; 2001. URL: http://nbocc.org.au/view-document-details/cpg-clinical-practiceguidelines-for-the-management-of-early-breast-cancer-2nd-ed (accessed January 2010).
112. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology, breast cancer. v.1.2009. Fort Washington, PA: NCCN; 2009. URL: www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed January 2010).
113. Grunfeld E, Dhesy-Thind S, Levine M, Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ 2005;172:1319-20.
114. Pestalozzi B, Castiglione M, ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl. 2):7-10.
115. Temple LK, Wang EE, McLeod RS. Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care. CMAJ 1999;161:1001-8.
116. National Institute of Health and Clinical Excellence (NICE). Breast cancer (early): paclitaxel: guidance. TA108. London: NICE; 2006. URL: http://guidance.nice.org.uk/TA108/Guidance/pdf/English (accessed January 2010).
117. National Institute of Health and Clinical Excellence (NICE). Breast cancer (early): trastuzumab: guidance. TA107. London: NICE; 2006. URL: http://guidance.nice.org.uk/TA108/Guidance/pdf/English (accessed January 2010).
118. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008;371:29-40.
119. Galante E, Guzzon A, Gallus G, Mauri M, Bono A, De Carli A, et al. Prognostic significance of the growth rate of breast cancer: preliminary evaluation on the follow-up of 196 breast cancers. Tumori 1981;67:333-40.
120. Lundgren B. Observations on growth rate of breast carcinomas and its possible implications for lead time. Cancer 1977;40:1722-5.
121. Spratt JS. The relationship between the rates of growth of cancers and the intervals between screening examinations necessary for effective discovery. Cancer Prev Detect 1981;4:301-5.
122. Arnerlov C, Emdin SO, Lundgren B, Roos G, Soderstrom J, Bjersing L, et al. Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction. Correlations to clinical and histopathologic factors in a screened population. Cancer 1992;70:1928-34.
123. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res 2008;10:R41.
124. Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ. Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 1996;78:1220-8.
125. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007;13:7357-62.